In vitro generation of primary cultures of human hyalocytes

Raffaele Nuzzi,1 Loredana Bergandi,2 Lorenzo Coda Zabetta,1 Laura D’Errico,2 Francesco Riscaldino,1 Silvia Menegon,2 Francesca Silvagno2

1Eye Clinic Section, Department of Surgical Sciences, University of Torino, Torino, Italy; 2Department of Oncology, University of Torino, Torino, Italy

Purpose: A growing number of studies on animal models have demonstrated that some ocular diseases are the result of the interaction between hyalocytes and the ocular inflammatory setting. Endogenous and exogenous substances might alter the structure and behavior of hyalocytes that can contribute to the pathogenesis of some ocular diseases. Obtaining primary cultures of human hyalocytes could help understand the role of these cells in response to different treatments.

Methods: Hyalocytes were isolated from eyes of 54 patient volunteers subjected to vitrectomy for different clinical reasons. By testing different matrices and growth media, we reproducibly generated primary cultures of hyalocytes that we characterized morphologically and biologically, basally and upon treatment with several agents (basic fibroblast growth factor (bFGF), transforming growth factor beta 1 (TGF-β), platelet-derived growth factor subunit-BB (PDGF-BB), ascorbic acid, dexamethasone, and hydrogen peroxide).

Results: We were able to generate primary cultures from vitreous human samples, growing the cells on collagen-coated plates in Iscove’s modified Dulbecco’s medium supplemented with 10% fetal bovine serum; primary cells expressed the hyalocyte markers. Specific cytoskeletal modifications were observed upon treatment with bFGF, TGF-β, PDGF-BB, ascorbic acid, dexamethasone, and hydrogen peroxide. Only bFGF was able to promote cell growth and hyaluronic acid production.

Conclusions: We describe for the first time the generation and the characterization of primary cultures of human hyalocytes from living donors. Although human hyalocytes share some characteristics with animal hyalocytes, human hyalocytes have their own features typical of the species, confirming how important human experimental models are for investigating human pathologies and their treatments.
better understanding the functions of human hyalocytes and their role in several vitreous-retinal diseases and highlighting the differences between human and animal hyalocytes.

**METHODS**

Reagents: Unless otherwise specified, reagents were purchased from Sigma-Aldrich (Milan, Italy), whereas plasticware was from Falcon (Becton Dickinson, Franklin Lakes, NJ).

Subjects: The study was performed in accordance with the Declaration of Helsinki for medical research involving human subjects in the period from February 2017 to June 2020 and was authorized by the local Ethical Committee (ref. number: 0077554). Signed, written informed consent was obtained from all patients accepting their enrolment in this study. All patients underwent a baseline ophthalmological examination before vitrectomy, including measurements of best-corrected visual acuity (BCVA), Goldmann applanation tonometry, and fundus examination. Fifty-four otherwise healthy patients with a history of vitreous-retinal diseases were randomly chosen among patients who underwent a 25 gauge or 27 gauge pars plan vitrectomy from the central vitreous cavity, for vitreoretinal disorders. The patients’ characteristics are listed in Table 1. The following clinical characteristics were recorded, and patients presenting one or more of the criteria were excluded from the study: presence of vitreous hemorrhages or hemovitreous, assumption of antioxidant integrators, impossibility of classifying vitreous degeneration or any of the other relevant parameters, infections, malignant neoplasia, or renal or hepatic failure. Patients presenting non-physiologic levels of glycemia and fibrinogen were also excluded.

Vitrectomy and preparation of vitreous cell primary culture: From each patient, vitreous samples (500–800 µl) were collected from the central vitreous cavity, at the beginning of the 25 or 27 gauge pars plana mini-invasive vitrectomy with non-contact technique (BIOM). Samples were stored in a 15 ml tube containing Iscove’s modified Dulbecco’s medium (IMDM; Waltham, MA) supplemented with 10% fetal bovine serum (FBS), 1% glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. To increase the rate of hyalocyte isolation from the vitreous body, vitreous samples were incubated for 1 h at 37 °C in a shaking incubator with 1 mg/ml collagenase (Sigma, Milan, Italy) diluted in IMDM. After the digestion, the vitreous bodies were centrifuged at 300 × g for 5 min. The obtained pellet was resuspended in IMDM, and collagenase-treated and -free cells were seeded for primary culture in a six-well plastic culture plate coated with collagen I (Cellware, Corning, BioCoat, VWR, Radnor, PA), and cultured at 37 °C in an incubator in the presence of 5% CO₂ in the following different growth conditions: IMDM (+ 10% FBS) or stem cell medium [18] or F12 medium (+ 10% FBS). The medium was changed twice a week.

Cell proliferation assay: To evaluate cell viability, about 3,000 cells/well were seeded in triplicate in 96-well culture plates, in the presence of the different drugs. In each collagen-coated well, cells were seeded in 200 µl of 10% FBS IMDM containing the following agents: 10 ng/ml of basic fibroblast growth factor (bFGF), 5 ng/ml of transforming growth factor beta 1 (TGF-β), 10 ng/ml of platelet-derived growth factor subunit-BB (PDGF-BB), 200 µg/ml of ascorbic acid (AsA), 1 mg/ml of dexamethasone (DEX), and 5 µM of hydrogen peroxide (H₂O₂). Cell growth was measured after 6 days of treatment by staining the wells with crystal violet, a dye that stains DNA to have a direct visual assessment of cells after treatment. Then, crystal violet was solubilized with 10% acetic acid, and the absorbance was read at 562 nm, on the spectrophotometer.

Immunofluorescence: About 4,000 cells/well were seeded on coverslips in a 24-well plate. After 24 h, the cells were fixed in 4% paraformaldehyde in PBS (1X; 137 mM NaCl; 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄, pH 7.4) for 10 min at room temperature. The cells were then washed with PBS 1X for 5 min, incubated with blocking solution (4% BSA in PBS 1X) at room temperature for 30 min, and finally, incubated with CD45 fluorochrome-conjugated antibody (2D1, 1:100 in 2% BSA) and phalloidin (1:40 in 2% BSA; BD, Franklin Lakes, NJ). The slides were washed with PBS and incubated with 4′,6-diamidino-2-phenylindole (DAPI; 1:10,000 in 2% BSA) for 10 min at room temperature. Finally, the slides were washed twice with PBS and mounted.

Real-time quantitative reverse transcription PCR (qRT-PCR): From five patients, vitreous samples were individually collected at the beginning of the 25 gauge pars plana from the central vitreous cavity and immediately centrifuged at 13,800 × g for 10 min. The clear supernatant was discarded, whereas the cellular component and debris (in situ vitreous cells) were immediately frozen at −20 °C until analysis. From six other patients, primary cultures were set up: The cells were seeded on six-multiwell plates in 10% FBS IMDM and cultured for 3 weeks (cultured vitreous cells). Then, the in situ and cultured vitreous cells were washed with PBS 1X, and total RNA was extracted with the Cells-to-CT™ 1-Step PowerSYBR® Green Kit (Ambion; Thermo Fisher Scientific, Waltham, MA) as previously described [19,20] and following the manufacturer’s instruction. Twenty micro-liters of RNA were used for retrotranscription using the SensiFAST™ cDNA Synthesis Kit (Bioline, Aurogene Srl, NJ).
| N° | Age | Gender | Intervention     | Reason for the intervention                       |
|----|-----|--------|------------------|---------------------------------------------------|
| 1  | 73  | F      | VTC 25 G         | Macular hole                                      |
| 2  | 81  | M      | VTC 25 G         | Spinteropia                                       |
| 3  | 76  | M      | VTC 25 G         | Macular pucker                                    |
| 4  | 77  | F      | VTC 25 G         | Dislocated IOL                                    |
| 5  | 81  | F      | VTC 25 G         | Retinal detachment                                |
| 6  | 79  | M      | VTC 25 G         | Retinal detachment on macular pucker              |
| 7  | 56  | F      | VTC 25 G+FACO+IOL| Spinteropia + macular pucker + cataract           |
| 8  | 40  | M      | VTC 25 G         | Retinal atrophy                                   |
| 9  | 77  | M      | VTC 25 G         | Macular pucker                                    |
| 10 | 75  | F      | VTC 25 G+FACO+IOL| Macular pucker+cataract                           |
| 11 | 80  | M      | VTC 25 G         | Macular pucker                                    |
| 12 | 70  | M      | VTC 25 G+FACO+IOL| Macular pucker+cataract                           |
| 13 | 78  | M      | VTC 25 G+FACO+IOL| Macular pucker+cataract                           |
| 14 | 77  | F      | VTC 27 G+FACO+IOL| Macular pucker+cataract                           |
| 15 | 52  | M      | VTC 25 G         | Retinal detachment                                |
| 16 | 66  | M      | VTC 25 G+FACO+IOL| Diabetic retinopathy+cataract                     |
| 17 | 74  | F      | VTC 25 G+FACO+IOL| Retinal detachment+cataract                       |
| 18 | 75  | M      | VTC 27 G         | Macular pucker                                    |
| 19 | 54  | F      | VTC 25 G+FACO+IOL| Macular hole+cataract                             |
| 20 | 52  | M      | VTC 25 G+FACO+IOL| Macular hole+cataract                             |
| 21 | 79  | F      | VTC 27 G         | Macular pucker                                    |
| 22 | 66  | F      | VTC 25 G         | Diabetic retinopathy                               |
| 23 | 55  | M      | VTC 25 G+FACO+IOL| Retinal detachment+cataract                       |
| 24 | 63  | M      | VTC 25 G         | Macular pucker                                    |
| 25 | 78  | M      | VTC 25 G         | Macular pucker                                    |
| 26 | 52  | F      | VTC 25 G+FACO+IOL| Retinal detachment+cataract                       |
| 27 | 87  | M      | VTC 25 G+FACO+IOL| Macular pucker+cataract                           |
| 28 | 66  | M      | VTC 25G           | Macular pucker                                    |
| 29 | 74  | F      | VTC 25 G+FACO+IOL| Macular pucker+cataract                           |
| 30 | 83  | F      | VTC 25 G         | Macular pucker                                    |
| 31 | 85  | M      | VTC 25 G         | Retinal detachment                                |
| 32 | 82  | M      | VTC 25 G         | Macular pucker+cataract                           |
| 33 | 86  | M      | VTC 25 G         | Macular pucker+cataract                           |
| No | Age | Gender | Intervention               | Reason for the intervention                  |
|----|-----|--------|----------------------------|---------------------------------------------|
| 34 | 78  | M      | VTC 25 G                   | Spinteropia+cataract                        |
| 35 | 70  | M      | VTC 27 G+FACO+IOL          | Macular pucker+cataract                     |
| 36 | 64  | F      | VTC 25 G                   | Retinal detachment                          |
| 37 | 69  | F      | VTC 25 G+FACO+IOL          | Retinal detachment+cataract                 |
| 38 | 65  | M      | VTC 25 G+FACO+IOL          | Macular hole+cataract                       |
| 39 | 41  | F      | VTC 25 G+FACO+IOL          | Retinal detachment+cataract+macular pucker  |
| 40 | 70  | F      | VTC 25 G                   | Macular hole                                |
| 41 | 70  | F      | VTC 25 G+FACO+IOL          | Retinal detachment+cataract                 |
| 42 | 70  | M      | VTC 25 G                   | Retinal detachment                          |
| 43 | 48  | F      | VTC 25 G                   | Diabetic retinopathy                        |
| 44 | 65  | M      | VTC 25 G                   | Macular pucker                              |
| 45 | 55  | M      | VTC 25 G                   | Retinal detachment                          |
| 46 | 70  | F      | VTC 25 G                   | Macular hole                                |
| 47 | 68  | M      | VTC 25 G                   | Macular pucker                              |
| 48 | 66  | F      | VTC 25 G+FACO+IOL          | Retinal detachment+cataract                 |
| 49 | 75  | F      | VTC 25 G                   | Macular hole                                |
| 50 | 68  | M      | VTC 25 G                   | Macular pucker                              |
| 51 | 73  | F      | VTC 25 G                   | Macular hole                                |
| 52 | 63  | M      | VTC 25 G+FACO+IOL          | Retinal detachment+cataract                 |
| 53 | 74  | F      | VTC 25 G                   | Macular pucker                              |
| 54 | 70  | M      | VTC 25 G                   | Retinal detachment                          |

List of patients randomly chosen among those undergone a 25 gauge or 27 gauge pars plana vitrectomy from the central vitreous cavity for vitreoretinal disorders. VTC 25 G: 25 gauge vitrectomy; VTC 27 G: 27 gauge vitrectomy; IOL: intra ocular lens; FACO: phacoemulsification.
Rome, Italy) at 42 °C for 15 min and 85 °C for 5 min. cDNAs were stored at −80 °C until PCR analysis. PCR primers were designed using NCBI/Primer-BLAST and synthesized by Sigma-Merck (Merck Life Science S.r.l., Milan, Italy). The SensiFAST™ SYBR® No-ROX Kit (Bioline, Aurogene Srl) was used to perform qRT-PCR following the manufacturer’s protocol: 1 cycle at 95 °C for 2 min, 40 cycles at 95 °C for 5 s, 1 cycle at 60 °C for 30 s, and 1 cycle at 95 °C for 1 min. The PCR primers (Table 2) were designed using NCBI/Primer-BLAST and synthesized by Sigma-Merck (UK). Gene expression analysis was performed with CFX Manager software (BioRad, Hercules, CA). Each reaction was performed in triplicate. The specificity of the PCRs was confirmed with melt curve analysis. Nonspecific amplifications were never detected.

HA assay: To perform the HA assay, 5,000 hyalocytes/well were seeded in 48-well plates containing 0.5 ml IMDM (+10% FBS) and stimulated for 6 days with different agents: 10 ng/ml of bFGF, 5 ng/ml of TGF-β, 10 ng/ml of PDGF-BB, 200 µg/ml of AsA, 1 mg/ml of DEX, and 5 µM of H₂O₂. HA levels were detected in 10 µl of primary culture supernatant using the hyaluronic acid (human) AlphaLISA® immunoassay kit (PerkinElmer, Waltham, MA). Two different types of cells, lung adenocarcinoma (A549) cells (ATCC, LGC Standards S.r.l., Milan, Italy), were used for comparison purposes based on their different HA production in 6 days [21,22]. HA levels were measured with an EnVision plate reader (PerkinElmer), and the values are expressed as ng HA/ng cell protein.

Statistical analysis: Statistical analysis of the data was performed using analysis of variance (ANOVA) with Tukey’s post-hoc correction. A p value of less than 0.05 was considered statistically significant. All data were expressed as mean ± standard deviation (SD).

RESULTS

Optimization of hyalocyte culture conditions: From 54 vitrectomy samples representative of different eye diseases, 54 different cell cultures were set up in about 6 weeks as described in the Method section, and different growth media were tested, using collagenase treatment or not, to allow the setting of primary cultures. Samples subjected to collagenase treatment showed low viability which did not allow the establishment of primary cultures. IMDM supplemented with serum turned out to be the best growth condition for samples that were directly seeded in collagen-coated plates. Like most primary cultures, these cells were not immortalized, but they were able to grow in vitro for 1–3 months. The cultures contained cells showing two different morphologies: elongated (or spherical), with a few stout processes (Figure 1A), or stellate, with some short processes (Figure 1B).

To confirm that the cells growing in culture were hyalocytes, we performed immunofluorescent staining with antibodies recognizing CD45. As shown in Appendix 1, the immunofluorescence detection demonstrated that these cells expressed the CD45 antigen [9,13]. Moreover, qRT-PCR was performed to check the presence of CD45, CD11a, CD64, and CD163 and the absence of CD68 and CD11b in the in situ and in cultured vitreous cells. There were no significant differences in the expression of the hyalocyte mRNA markers between the in situ and cultured cells (Figure 2), demonstrating that the primary cultures retained the characteristics of the cells extracted from the tissue. Importantly, the

| Gene       | Forward primer (5’-3’)         | Reverse primer (5’-3’)         | References |
|------------|---------------------------------|---------------------------------|------------|
| hCD45      | CTGACATCATCACCTAGCAG            | TGCTGTAGTCAATCCAGTGG           | [37]       |
| hCD11a     | TGGAGGAGGCTATTTGGGTAC           | CGGCCCATGTGCTGGTAT             | [38]       |
| hCD64      | GCCACAGAGGATGAAATGT            | CATGAACCAGACAGGATGG           | [39]       |
| hCD163     | TCAGAGTTCCAACCAGAAGGAG         | TGTCATCTGAGTCTTTGTCC           | [40]       |
| hCD68      | TGGATTCATGCGAGAACCTCC          | GCACCAGTACGTCAGGACACA          | [41]       |
| hCD11b     | GGCCATGCAAGATACAGGAGG          | CTGGGGGTGGGATTTTCT             | [41]       |
| hCD16      | TCAGAGTTCCAACCAGC             | GATATGGACTTTCTAGCTGACACC       | [42]       |
| H vimentin | AGGAAATGGGCTGTCACCTCGTAATA     | GGAGGTCTGGTTGTAAGAACTAGAGCT    | [43]       |
| hGFAP      | ACATCGAGATCGCCACCTAC          | ACATACACATCCTGTGCTCC          | [44]       |
| hRbp       | GCTGCTGGAGAATGAGGAAACTC        | GGCTGGTAGGATGAGTGGG           | [45]       |
| B2M        | AGCAAGGACTGGGTTCCTACTC         | ATGTCTCGATCCCCACCTA            | [46]       |

Abbreviations: hGFAP, human glial fibrillary acidic protein; hRbp, human retinaldehyde binding protein 1; B2M, beta-2-Microglobulin used as reference gene to normalize the cDNA in different samples; qRT-PCR, quantitative real-time polymerase chain reaction.
primary cultures of hyalocytes did not contain any contaminating cell types as mRNA expression of CD68 and CD11b was not detected (Figure 2). In further analysis, we could not find amplification products for CD16, vimentin, GFAP, and Rlbp, chosen as the typical markers for macrophages, neutrophils, fibroblasts, and retinal glial and human RPE cells (data not shown), respectively, suggesting the absence of contaminating cells in the primary cultures of hyalocytes.

Moreover, as hyalocytes are known to produce HA [23], we investigated the accumulation of this molecule in the supernatant of the cell cultures. As expected, we detected the presence of HA (0.861 ± 0.06 ng/ng cellular protein; Figure 3), further sustaining that the primary cultures were enriched in hyalocytes. Overall, the data show that we were able to set up primary cultures of cells that display morphological, immunogenic, and functional characteristics typical of hyalocytes.

Biologic effects of treatments: To understand whether the environmental conditions could modify the growth and the shape of the cells, as well as their biologic activity, we exposed the cultures to different agents known to affect non-human hyalocytes [3,24,25]. One of the aims of this study was to compare the difference between human and animal hyalocytes, to better understand the role of human hyalocytes in the pathogenesis of different ocular diseases. In the experiments, we tested the effects of 10 ng/ml bFGF, 5 ng/ml TGF-β, 10 ng/ml PDGF-BB, 200 µg/ml AsA, 1 mg/ml DEX, and 5 µM H₂O₂.

Figure 1. In vitro primary cultures microphotographies. Cells show two main morphologies: elongated (or spherical), with a few stout processes (A), or stellate, with some short processes (B). Scale bar: 0.25 mm.

Figure 2. qRT-PCR assay. Relative mRNA expression of CD45, CD11a, CD64, CD163, CD68, and CD11b in situ vitreous cells and in cultured vitreous cells. Measurements were performed in triplicate.
To assess the effects of the treatments on cell shape and cytoskeletal filament organization, hyalocytes were stained with phalloidin. As shown in Figure 4, the untreated hyalocytes showed a filamentous actin cytoskeleton organized in numerous but thin stress fibers (Figure 4A). Lamellipodia were observed after 5 days of treatment with bFGF (Figure 4B), suggesting an increased cell motility. TGF-β (Figure 4C) and PDGF-BB (Figure 4D) induced actin cytoskeleton reorganization in long and thick actin stress fibers. The supplementation with AsA inhibited actin polymerization and induced the appearance of small and rounded cells (Figure 4E). DEX (Figure 4F) induced actin fiber organization in two different patterns: short stress fibers and thick filamentous fibers close to the cell membrane. Finally, \( \text{H}_2\text{O}_2 \) caused the appearance of thick filamentous actin fibers close to the cell membrane (Figure 4G).

We also evaluated the proliferation of hyalocytes in the same experimental conditions. As shown in Figure 5, the increase in cell number was clear upon the supplement of 10 ng/ml of bFGF versus untreated cells (NT; resulting in a threefold increase in the proliferation rate). The TGF-β, PDGF-BB, DEX, and \( \text{H}_2\text{O}_2 \) treatments had no statistically significant effect on cell proliferation.

As the identification of agents that could increase HA production is important for their possible pharmacological application for vitreous regeneration, we evaluated the effect of these substances on HA production. As shown in Figure 3, the level of hyaluronic acid in the cellular supernatant was statistically significantly increased after treatment with bFGF (1.95 \( \pm \) 0.08 ng/ng cellular protein), whereas the other treatments did not modify production of hyaluronic acid.

**DISCUSSION**

Vitreous has long been considered an inert fluid with the only function of keeping the retina adherent to the posterior eye’s surface. Recently, many researchers have examined vitreous properties and functions to understand whether they could play a role in the pathogenesis of some ocular diseases. Although the presence of cells inside the vitreous has been known for more than a century, their role has remained unknown for many decades, and even today, it is uncertain. Nevertheless, much evidence shows that hyalocytes are involved in the different ocular pathogenesis. The interaction between an inflammatory environment and hyalocytes could stimulate these cells to change their behavior and gain contractile function \([15,24]\). Due to this new feature, hyalocytes may pull the internal limiting membrane of the retina, causing the formation of macular pucker or macular hole \([8,13-16]\). Schumann et al. \([13]\) showed that there is a positive correlation between macular hole size and cell density at the internal limiting membrane. However, the proliferation of hyalocytes could represent one of the possible ways to obtain vitreous regeneration. Although synthetic vitreous substitutes are still the only choice after vitrectomy, supplementation with bFGF during the expansion of porcine hyalocytes appears to be a promising approach to gain enough cells within a short time frame useful for regenerating human vitreous \([3]\).
In this context, based on the existing studies on animal hyalocytes, the availability of cultures of human hyalocytes to investigate treatments affecting their growth and biologic properties is necessary. For the first time, this study provided a reproducible experimental technique for isolating and growing human hyalocytes in primary culture. Several growth conditions were tested to improve the rate of success in establishing primary cultures. In our experience, direct plating on collagen-coated dishes turned out to be more effective than collagenase pretreatment of cells derived from surgical specimens. Moreover, among the tested media, IMDM with the addition of FBS provided the best results. In these conditions, we obtained primary cultures that remained alive for several months. Previous studies on hyalocytes were clearly different from ours. Researchers were able to obtain hyalocyte cell lines in active proliferation only from animals, whereas the few studies conducted on human cells have allowed only to document the presence of hyalocytes in the humor vitreous and to study their morphology [8,9,14,17,26].

Once we were able to generate hyalocyte cultures, we investigated their behavior in the presence of different stimulations. bFGF is involved in cell survival activities, mitogenic processes, embryonic development, cell growth, morphogenesis, tumor growth, and invasion [27]. Although it has been shown that bFGF can inhibit the differentiation of embryonic stem cells, and it is necessary for the cells to remain in an undifferentiated state [27], at the same time, bFGF, in conjunction with the bone morphogenetic protein 4 (BMP4), promotes differentiation of stem cells to mesodermal lineages [28]. In agreement with the study by Sommer et al. [3] on

Figure 4. Immunofluorescent staining. Hyalocytes were stained with phalloidin, showing the cell shape and cytoskeletal changes after 6 days of exposure to the different treatments (doses are indicated in the Methods section). A: Control. B: Basic fibroblast growth factor (bFGF). C: Transforming growth factor beta 1 (TGF-β). D: Platelet-derived growth factor subunit-BB (PDGF-BB). E: Ascorbic acid (AsA). F: Dexamethasone (DEX). G: \( \text{H}_2\text{O}_2 \).
porcine hyalocytes, the present experiments revealed that bFGF is endowed with growth-promoting activity, increases HA production, and induces morphological changes compatible with a motile phenotype, suggesting that bFGF could stimulate hyalocytes to gain new functions and a different behavior which could be related to the pathogenesis of various ocular diseases.

TGF-β could be one of the molecules produced by hyalocytes that have a role in the modulation of the retinal microenvironment. Sommer et al. showed that TGF-β inhibits the proliferation of porcine hyalocytes [3]; however, in this study we did not observe differences in cell growth upon TGF-β treatment. The difference between these results could be ascribable to the intrinsic difference between human and porcine hyalocytes. As the acquisition of contractile functions of hyalocytes is mandatory for the pathogenesis of macular pucker [8,15,16], we investigated the effects of TGF-β on actin cytoskeleton. In agreement with Sommer et al. [3], we observed that TGF-β increased the thickness of the actin filaments within the cells.

Another difference between our and Sommer’s work is related to AsA. In their study, AsA clearly stimulated the proliferation of porcine hyalocytes [29]. Noda et al. [24] demonstrated that bovine hyalocytes express platelet-derived growth factor α and β (PDGF-α and PDGF-β) receptors, whose activation promotes cell growth and migration.

Another important aspect that could emerge from this study is the possibility of exploiting the novel cell culture protocol to investigate the interaction between hyalocytes and other cell lines. Nuzzi et al. [30] analyzed the interaction between vitreous environment, cultured RPE (ARPE-19) cells, and mesenchymal stems cells (MSCs). ARPE-19 cells could modify the effect of different agents on human hyalocytes. In this context, it could be interesting to study, proving a reproducible experimental model, the interaction between human hyalocytes, ARPE-19, and different drugs. Nuzzi et al. demonstrated that MSCs are sensible to corticosteroid and to ARPE-19 cells. Moreover, DEX inhibits the proliferation of human bone marrow MSCs, and the addition of RPE cells decreases the toxicity of DEX for MSCs. Future studies could investigate the role of MSCs in the metabolism of hyalocytes. This interaction could be important for treating age-related macular degeneration (AMD) [31]. Knowing the interaction between MSCs, hyalocytes, ARPE-19, and different agents like DEX is essential to improve the treatment of AMD and other ocular diseases [30,31].

Altogether, the present results show that although human hyalocytes share some characteristics with animal hyalocytes, human hyalocytes have their own features typical of the species, confirming how important the human experimental model for hyalocytes is for investigating human pathologies and their treatments. The novelty of this study was a protocol for generating primary hyalocyte cultures to study the growth, cytoskeleton changes, and HA production in response to different agents.

Novel approaches for vitreous replacement are needed to improve clinical therapy after vitrectomy. After
vitreous-retinal surgery, it is necessary to use a vitreous substitute that has the functions of ensuring retinal adherence, avoiding intraocular hemorrhage, and maintaining correct eye tone [32,33]. Although some substances like silicon have these features and can be allowed inside the eye for several days after surgery, all these vitreous substitutes can cause side effects, such as glaucoma, cataract, and retinal toxicity [32-34]. For these reasons, several researchers have investigated the possibility of generating new materials to substitute the human vitreous. In addition to studies on hydrogels and natural polymers, studies on the regeneration of human vitreous are extremely promising [34-36].

To proceed in this direction, it is essential to improve our knowledge of the vitreous and its cell physiology. In this context, the possibility of isolating and growing human hyalocytes represents a big step forward, in particular for further investigations of potential positive or negative effects different growth factors.

**APPENDIX 1. IMMUNOFLUORESCENT STAINING (GREEN SIGNAL) WITH ANTIBODY RECOGNIZING THE LEUKOCYTE COMMON ANTIGEN (CD45).**

To access the data, click or select the words “Appendix 1.”

**ACKNOWLEDGMENTS**

The authors would like to thank Prof. S. Giordano (University of Turin, Italy) for her helpful advice and suggestions, M. Colzani (Perkin Elmer Italia Spa) and Prof. M. Gallicchio (University of Turin, Italy) for providing scientific input and access to the EnSight instrument (financed by Compagnia di San Paolo) for this project. Funding: supported by Public University Funds.

**REFERENCES**

1. Bishop PN. Structural macromolecules and supramolecular organisation of the vitreous gel. Prog Retin Eye Res 2000; 19:323-44. [PMID: 10749380].

2. Bishop PN, Takanosu M, le Goff M, Mayne R. The role of the posterior ciliary body in the biosynthesis of vitreous humour. Eye (Lond) 2002; 16:454-60. [PMID: 12101453].

3. Sommer F, Pollinger K, Brandl F, Weiser B, Tesmar J, Torsten B, Gopferich A. Hyalocyte proliferation and ECM accumulation modulated by bFGF and TGF-β1. Graefes Arch Clin Exp Ophthalmol 2008; 246:1275-84. [PMID: 18461346].

4. Szirmai JA, Balazs EA. Studies on the structure of the vitreous body. III. Cells in the cortical layer. AMA Arch Ophthalmol 1958; 59:34-48. [PMID: 13486991].

5. Haddad A, André JC. Hyalocyte-Like Cells are more numerous in the Posterior Chamber than they are in the Vitreous of the Rabbit Eye. Exp Eye Res 1998; 66:709-18. [PMID: 9657903].

6. Ogawa K. Scanning Electron Microscopic Study of Hyalocytes in the Guinea Pig Eye. Arch Histol Cytol 2002; 65:263-8. [PMID: 12389665].

7. Sakamoto T, Ishibashi T. HYALOCYTES: Essential Cells of the Vitreous Cavity in Vitreoretinal Pathophysiology? Retina 2011; 31:222-8. [PMID: 21240043].

8. Schumann RG, Gandorfer A, Ziada J, Scheler R, Schaumberger MM, Wolf A, Kampik A, Haritoglou C. Hyalocytes in idiopathic epiretinal membranes: a correlative light and electron microscopic study. Graefes Arch Clin Exp Ophthalmol 2014; 252:1887-94. [PMID: 25377434].

9. Lazarus HS, Hageman GS. In Situ Characterization of the Human Hyalocyte. Arch Ophthalmol 1994; 112:1356-62. [PMID: 7945040].

10. Llombart C, Nacher V, Ramos D, Lullo M, Carretero A, Navarro M, Melgarrevo J, Armengol C, Rodriguez-Baeza A, Mendes-Jorge L, Ruberte J. Morphological characterization of pecteneal hyalocytes in the developing quail retina. J Anat 2009; 215:280-91. [PMID: 19566699].

11. Qiao H, Hisatomi T, Sonoda K-H, Kura S, Sassa Y, Kinoshita S, Nakamura T, Sakamoto T, Ishibashi T. The characterisation of hyalocytes: the origin, phenotype, and turnover. Br J Ophthalmol 2005; 89:513-7. [PMID: 15774935].

12. Sano Y, Matsuda K, Okamoto M, Takehana K, Hirayama K, Taniyama H. Characterization of equine hyalocytes: their immunohistochemical properties, morphologies and distribution. J Vet Med Sci 2016; 78:937-42. [PMID: 26888584].

13. Schumann RG, Hagenau F, Haritoglou C, Wolf A, Schaumberger MM, Kampik A, Gandorfer A. Cells at the vitreoretinal interface in small full-thickness macular holes. Retina 2015; 35:1158-65. [PMID: 25621947].

14. Schumann RG, Eibl KH, Zhao F, Scheerbaum M. Renate Scheler, Schaumberger M M, Wehnes H, Walch A K, Haritoglou C, Kampik A, Gandorfer A. Immunocytochemical and Ultrastructural Evidence of Glial Cells and Hyalocytes in Internal Limiting Membrane Specimens of Idiopathic Macular Holes. Invest Ophthalmol Vis Sci 2011; 52:7822-34. [PMID: 21900375].

15. Kohno R-i, Hata Y, Kawahara S, Kita T, Arita R, Mochizuki Y, Asello LP, Ishibashi T. Possible contribution of hyalocytes to idiopathic epiretinal membrane formation and its contraction. Br J Ophthalmol 2009; 93:1020-6. [PMID: 19429593].

16. Joshi M, Agrawal S, Christoforidis JB. Inflammatory Mechanisms of Idiopathic Epiretinal Membrane Formation. Mediators Inflamm 2013; 2013:[PMID: 24324293].

17. Grabner G, Boltz G, Förster O. Macrophage-like properties of human hyalocytes. Invest Ophthalmol Vis Sci 1980; 19:333-40. [PMID: 7358486].

18. Jung P, Sato T, Merlos-Suárez A, Barriga FM, Iglesias M, Rossell D, Auer H, Gallardo M, Blasco MA, Sanch E, Clevers
20. Canosa S, Bergandi L, Macri C, Charrier L, Pascher C, Carosso A, Di Segni N, Silvagno F, Gennarelli G, Benedetto C, Revelli A. Morphokinetic analysis of cleavage stage embryos and assessment of specific gene expression in cumulus cells independently predict human embryo development to expanded blastocysts: a preliminary study. J Assist Reprod Genet 2020; 37:1409-20. [PMID: 32436046].

21. Chow G, Tauler J, Mulshine JL. Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer. J Biomed Biotechnol 2010; 2010:485468- [PMID: 20671927].

22. Anitua E, Sánchez M, Zaldueondo MM, de la Fuente M, Prado R, Orive G, Andia I. Fibroblastic response to treatment with different preparations rich in growth factors. Cell Prolif 2009; 42:162-70. [PMID: 19250293].

23. Nishitsuka K, Kashiwagi Y, Tojo N, Kanno C, Takahashi Y, Yamamoto T, Heldin P, Yamashita H. Hyaluronan production regulation from porcine hyalocyte cell line by cytokines. Exp Eye Res 2007; 85:539-45. [PMID: 17707370].

24. Noda Y, Hata Y, Hisatomi T, akamura Y, Hirayama K, Miura Y, Nakao S, Fujisawa K, Sakamoto T, Ishibashi T. Functional properties of hyalocytes under PDGF-rich conditions. Invest Ophthalmol Vis Sci 2004; 45:2107-14. [PMID: 15223783].

25. Hata Y, Nakao S, Kohno R-I, Oba K, Kata T, Miura M, Sassa Y, Schering A, Ishibashi T. Role of tumour necrosis factor-α (TNFα) in the functional properties of hyalocytes. Br J Ophthalmol 2011; 95:261-5. [PMID: 21030411].

26. Kashiwagi Y, Nishitsuka K, Takamura H, Yamamoto T, Yamashita H. Cloning and characterization of human vitreous tissue-derived cells. Acta Ophthalmol 2011; 89:538-43. [PMID: 19878119].

27. Haghighi F, Dahlmann J, Nakhaei-Rad S, Lang A, Kutschka I, Zenker M, Kessah G, Piekorz RP, Ahmadian MR. bFGF-mediated pluriptotent maintenance in human induced pluripotent stem cells is associated with NRAS-MAPK signaling. Cell Commun Signal 2018; 16:96-[PMID: 30518391].

28. Sudsheer S, Bhushan R, Fauler B, Lehrhach H, Adjaye J. FGF inhibition directs BMP4-mediated differentiation of human embryonic stem cells to syncytiotrophoblast. Stem Cells Dev 2012; 21:2987-3000. [PMID: 22724507].

29. Sommer F, Brandl F, Weiser B, Tesmar J, Blunk T, Göpferich A. FACS as useful tool to study distinct hyalocyte populations. Exp Eye Res 2009; 88:995-9. [PMID: 19073178].

30. Nuzzi R, Gunetti M, Rustichelli D, Roagba A, Fronticelli Bardelli F, Fagioli F, Ferrero I. Effect of In Vitro Exposure of Corticosteroid Drugs, Conventionally Used in AMD Treatment, on Mesenchymal Stem Cells. Stem Cells Int 2012; 2012:946090- [PMID: 22693520].

31. Ding SLS, Kumar S, Mok PL. Cellular Reparative Mechanisms of Mesenchymal Stem Cells for Retinal Diseases. Int J Mol Sci 2017; 18. [PMID: 28788088].

32. Donati S, Caprani SM, Airaghi G, Vinciguerra R, Bartalena L, Testa F, Mariotti C, Porta G, Simonelli F, Azzolini C. Vitreous substitutes: the present and the future. BioMed Res Int 2014; 2014:351804- [PMID: 24877085].

33. Kleinberg TT, Tzekov RT, Stein L, Ravi N, Kaushal S. Vitreous substitutes: a comprehensive review. Surv Ophthalmol 2011; 56:300-23. [PMID: 21601902].

34. Szurman P. Vitreous Substitute in Retinal Detachment Surgery - Why We Need a New Tamponade Strategy. Klin Monatsbl Augenheilkd 2017; 234:1094-102. [PMID: 28895627].

35. Singh J, Ramaesh K, Wharton SB, Cormack G, Chawla HB. Perfluorodecalin-induced intravitreal inflammation. Retina 2001; 21:247-51. [PMID: 11421015].

36. Yu Q, Liu K, Su L, Xia X, Xu X. Perfluorocarbon liquid: its application in vitreoretinal surgery and related ocular inflammation. BioMed Res Int 2014; 2014:250323-[PMID: 24800216].

37. Hyun J, Romero L, Riveron R, Flores C, Kanagavelu S, Chung KD, Alonso A, Sotolongo J, Ruiz J, Manukyan A, Chun S, Singh G, Salas P, Targan SR, Fukata M. Human intestinal epithelial cells express interleukin-10 through Toll-like receptor 4-mediated epithelial-macrophase crosstalk. J Innate Immun 2015; 7:87-101. [PMID: 25171731].

38. Zhao M, Wu X, Zhang Q, Luo S, Liang G, Su Y, Tan Y, Lu Q. RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1. Arthritis Res Ther 2010; 12:R227-[PMID: 21192791].

39. Schmitz V, Prata RB, Barbosa MG, Mendes MA, Brandão SS, Amadeu TP, Rodrigues LS, Ferreira H, Costa Fda M, Dos Santos JB, Pacheco Fdos S, Machado Ade M, Nery JA, Hacker Mde A, Sales AM, Pinheiro RO, Sarro EN. Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammation. In Erythema Nodosum Leprosum. PLoS Negl Trop Dis 2016; 10:e0004955-[PMID: 28895627].

40. Moeller JB, Nielsen MJ, Reichhardt MP, Schlosser A, Sorensen GL, Nielsen O, Tornoe I, Grønlund J, Nielsen ME, Jørgensen JS, Jensen ON, Mollenhauer J, Moestrup SK, Holmskov U. CD163-L1 is an endocytic macrophase protein strongly regulated by mediators in the inflammatory response. J Immunol 2012; 188:2399-409. [PMID: 22279103].

41. Michaud A, Pelletier M, Noël S, Bouchard C, Tchernof A. Markers of macrophage infiltration and measures of lipolysis in human abdominal adipose tissues. Obesity (Silver Spring) 2013; 21:2342-9. [PMID: 23408706].
42. Morris MC, Khan MN, Pichichero ME. A PCR-based method for quantifying neutrophils in human nasal secretions. J Immunol Methods 2017; 447:65-70. [PMID: 28454715].

43. Polimeni M, Gulino GR, Gazzano E, Kopecka J, Marucco A, Fenoglio I, Cesano F, Campagnolo L, Magrini A, Pietroistu A, Ghigo D, Aldieri E. Multi-walled carbon nanotubes directly induce epithelial-mesenchymal transition in human bronchial epithelial cells via the TGF-β-mediated Akt/GSK-3β/SNAIL-1 signalling pathway. Part Fibre Toxicol 2016; 13:[PMID: 27251132].

44. Bélanger M, Desjardins P, Chatauret N, Butterworth RF. Loss of expression of glial fibrillary acidic protein in acute hyperammonemia. Neurochem Int 2002; 41:155-60. [PMID: 12020615].

45. Carr A-J, Vugler AA, Yu L, Semo M, Coffey P, Moss SE, Greenwood J. The expression of retinal cell markers in human retinal pigment epithelial cells and their augmentation by the synthetic retinoid fenretinide. Mol Vis 2011; 17:1701-15. [PMID: 21738400].

46. Ricca C, Aillon A, Bergandi L, Alotto D, Castagnoli C, Silvagno F, Vitamin D. Receptor Is Necessary for Mitochondrial Function and Cell Health. Int J Mol Sci 2018; 19:[PMID: 29874855].

Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China. The print version of this article was created on 30 December 2020. This reflects all typographical corrections and errata to the article through that date. Details of any changes may be found in the online version of the article.